Mark Cuban has never been known for subtlety, and his April 21, 2026 appearance at Politico's Health Care Summit was no exception. Standing before lawmakers and industry insiders, the billionaire entrepreneur delivered a blunt message: stop being "wimps" and break up the healthcare conglomerates that are draining Americans dry. At the same time, his Cost Plus Drugs company made headlines for a different reason — helping Real Housewives of Beverly Hills star Brandi Glanville access affordable medication after a catastrophic medical ordeal that racked up nearly $200,000 in bills. Together, these two stories offer a window into everything broken about American healthcare, and what one persistent billionaire is trying to do about it.
Cuban at the Politico Summit: A Rare Voice for Real Reform
The Politico Health Care Summit draws the kind of crowd that tends to speak in careful, hedged language. Cuban did not. His message to Congress was direct: the dominant healthcare conglomerates and pharmacy benefit managers (PBMs) that control access to drugs, set prices, and steer billions in revenue to themselves need to be broken apart — and the lawmakers capable of doing it are too scared to act.
"Don't be a wimp," Cuban told the assembled legislators, according to Fierce Healthcare. He was urging support for the Break Up Big Medicine Act, a bipartisan bill introduced in February 2026 by Senators Elizabeth Warren (D-MA) and Josh Hawley (R-MO). The legislation would penalize vertically integrated healthcare companies — the kind that own insurance arms, pharmacy benefit managers, hospital networks, and drug distribution channels all under one roof.
Cuban's frustration isn't theoretical. He accused large healthcare organizations of systematic self-dealing: using their dominant market positions to steer partner companies away from competing networks or drug formularies. The effect, he argues, is a closed loop where patients pay more so that integrated corporations can profit at every step of their care.
What Is the Break Up Big Medicine Act?
The Break Up Big Medicine Act, introduced in February 2026, targets one of the most consequential structural problems in American healthcare: vertical integration. Over the past decade, major insurance companies have absorbed PBMs, specialty pharmacies, and even primary care practices. CVS Health owns Aetna and Caremark. UnitedHealth Group owns Optum, which runs pharmacies, medical groups, and a data analytics firm. Cigna owns Express Scripts.
This consolidation gives these companies extraordinary leverage. A PBM that's also owned by an insurer can set formularies that favor drugs with higher rebates, negotiate in ways that disadvantage independent pharmacies, and create barriers that make it harder for competitors — or transparency-focused upstarts like Cost Plus Drugs — to gain a foothold.
The Warren-Hawley bill would impose financial penalties on companies engaged in this kind of vertical integration. It's a rare piece of legislation with genuine bipartisan co-sponsorship, brought together by a progressive senator from Massachusetts and a populist conservative from Missouri. That alliance alone signals how broadly the frustration with healthcare consolidation cuts across political lines.
And yet, Cuban was candid about the bill's current status: it has almost no public backing. He claims 5 to 6 Senate Democrats are privately supportive but unwilling to say so publicly. The political economy of healthcare — in which the largest companies employ hundreds of thousands of workers and spend enormous sums on lobbying — makes even sympathetic lawmakers cautious.
What Are PBMs and Why Do They Matter?
Pharmacy benefit managers are the largely invisible middlemen of American drug pricing. They negotiate between drug manufacturers and insurers, managing formularies (the lists of covered drugs), processing prescriptions, and collecting rebates. In theory, they're supposed to lower drug costs. In practice, critics argue they've become profit centers that obscure pricing and often make drugs more expensive for patients while pocketing the difference.
The three largest PBMs — CVS Caremark, Express Scripts (owned by Cigna), and OptumRx (owned by UnitedHealth Group) — together manage the drug benefits of roughly 80% of Americans with prescription coverage. Their market dominance is precisely what Cuban objects to, and what the Break Up Big Medicine Act is designed to address.
Cuban's Cost Plus Drugs model is a direct rebuke of the PBM system. Instead of negotiating rebates and layering in middlemen fees, Cost Plus Drugs purchases generic medications directly from manufacturers at cost, adds a fixed 15% markup plus a small dispensing fee, and passes the result to consumers. The pricing is publicly listed. There are no hidden rebates, no formulary games, no opaque negotiations.
Cuban has called Cost Plus Drugs "the only truly transparent pricing pharmacy" — a claim that, given the opacity of the broader industry, is difficult to dispute.
Brandi Glanville's $200,000 Medical Nightmare
The story of Brandi Glanville reads like a case study in how American healthcare can fail even patients who are desperately seeking answers. The Real Housewives of Beverly Hills star spent approximately three years dealing with unexplained, debilitating symptoms: brain fog, joint pain, and — most visibly — severe facial disfigurement. She visited 21 different doctors. She racked up nearly $200,000 in medical bills. She chronicled the ordeal on her podcast, I Do, Part 2.
The diagnosis, when it finally came, was as straightforward as it was infuriating in retrospect: a ruptured right breast implant had been leaking silicone for years, clogging her lymph nodes and triggering systemic inflammation. A sonogram eventually revealed what years of medical appointments had missed.
According to reporting from Page Six, once Glanville had a diagnosis and needed medication to manage her recovery, the cost of those drugs became its own obstacle. Rachel Strauss, the CEO of PBM Princess (itself a consulting firm that helps patients navigate opaque drug pricing), turned to Cost Plus Drugs to source affordable medication for Glanville.
Cuban's response, per his statement to Page Six, was pointed: pharma "greed" had preyed on someone already suffering through a severe medical crisis. The framing is deliberate — Glanville is a public figure, her story is sympathetic and well-documented, and it illustrates the abstract problem of drug pricing in viscerally human terms.
How Cost Plus Drugs Actually Works
Mark Cuban co-founded the Mark Cuban Cost Plus Drug Company in 2022 with physician Alex Oshmyansky. The company operates as a direct-purchase marketplace for generic drugs, cutting out the traditional PBM intermediary entirely. Patients don't need insurance to use it — in many cases, they're better off without it, because the transparent prices are lower than what insurance would charge through a traditional pharmacy.
The model is straightforward: Cost Plus Drugs sources generics directly from manufacturers, lists its costs transparently on its website, adds a 15% markup and a $3 pharmacy dispensing fee, and charges a $5 shipping fee per order. For many generic drugs, this results in prices that are dramatically lower than what patients would pay at a traditional pharmacy even with insurance.
The service has listed over 2,500 medications and continues to expand. For patients managing chronic conditions — diabetes, hypertension, mental health — the savings can be substantial. The platform has also partnered with some self-insured employers and health systems to further extend its reach.
The Glanville case exemplifies both the strength and the limitation of the Cost Plus model. It works exceptionally well for generics. But for brand-name drugs, specialty medications, and the complex web of conditions requiring insurance coordination, the system still has gaps. Cuban's political advocacy is, in part, an acknowledgment that Cost Plus Drugs alone can't fix what's broken — systemic change requires legislative action.
What This Means: Cuban's Dual Strategy
What's notable about Cuban's positioning in April 2026 is that he's pursuing two parallel tracks simultaneously. On one hand, he's running a direct-to-consumer pharmacy that competes with the incumbent system by offering transparency. On the other, he's lobbying Congress to dismantle the structural conditions that make companies like Cost Plus Drugs necessary in the first place.
This is a coherent, if ambitious, strategy. The pharmacy generates revenue, proves the concept, and provides Cuban with concrete evidence that transparent pricing is viable. The political advocacy attempts to force the broader system to adopt similar principles — or at least remove the structural advantages that allow PBMs to maintain their dominance.
His willingness to call out the cowardice of sympathetic lawmakers — rather than simply applauding them for their private support — is strategically interesting. It applies public pressure, signals that he won't be satisfied with quiet encouragement, and positions him as an outsider willing to name names in an industry where most participants speak in careful euphemisms.
The Break Up Big Medicine Act faces long odds. Healthcare industry lobbying is among the most powerful in Washington, and the bill's bipartisan sponsorship, while symbolically significant, hasn't yet translated into votes. The Senate dynamics Cuban described — where members privately support the bill but won't say so publicly — suggest that the political cost of opposing the healthcare industry still outweighs the political benefit of standing up to it.
But Cuban has a history of playing long games. He built and sold Broadcast.com for $5.7 billion. He turned the Dallas Mavericks into a championship franchise. He's not making short-term bets on healthcare reform — he's constructing an argument, building infrastructure, and waiting for the political environment to shift.
Frequently Asked Questions
What is Mark Cuban's Cost Plus Drugs?
Cost Plus Drugs is a direct-purchase online pharmacy co-founded by Mark Cuban that sells generic medications at transparent, cost-plus pricing. The company buys drugs directly from manufacturers, adds a fixed 15% markup plus a small dispensing fee, and lists all prices publicly. Patients don't need insurance, and prices are often substantially lower than what traditional pharmacies charge.
What did Mark Cuban say at the Politico Health Care Summit in April 2026?
Cuban urged Congress to stop being "wimps" and support legislation to break up major healthcare conglomerates and pharmacy benefit managers. He specifically backed the Break Up Big Medicine Act, co-sponsored by Senators Elizabeth Warren and Josh Hawley, which would penalize vertically integrated healthcare companies. He claimed that 5-6 Democratic senators privately support the bill but are afraid to say so publicly.
What is the Break Up Big Medicine Act?
Introduced in February 2026 by Senators Elizabeth Warren (D-MA) and Josh Hawley (R-MO), the Break Up Big Medicine Act is bipartisan legislation that would impose penalties on healthcare companies that engage in vertical integration — owning insurance, pharmacy benefit management, distribution, and care delivery under a single corporate umbrella. The bill targets the consolidation that critics argue enables self-dealing and inflated drug prices.
How did Cost Plus Drugs help Brandi Glanville?
After Glanville's three-year medical crisis — which involved a ruptured breast implant leaking silicone, 21 doctor visits, and nearly $200,000 in medical bills — Rachel Strauss, CEO of PBM Princess, turned to Cost Plus Drugs to help Glanville access affordable medication during her recovery. Cuban used the case to highlight how pharmaceutical "greed" exploits patients already in vulnerable situations.
What are pharmacy benefit managers (PBMs) and why are they controversial?
PBMs are intermediaries that manage prescription drug benefits on behalf of insurers and employers. They negotiate with drug manufacturers, set formularies, and process claims. Critics argue that the three dominant PBMs — CVS Caremark, Express Scripts, and OptumRx — have used their market power to maintain opaque pricing, collect rebates that don't flow to patients, and disadvantage independent pharmacies. They collectively control drug benefits for roughly 80% of insured Americans.
Conclusion: The Fight Is Just Beginning
Mark Cuban's dual role — transparent pharmacy operator and vocal political advocate — is unusual in American business. Most billionaires who enter healthcare do so through investment; Cuban entered through disruption, and he's been unusually willing to name the institutions and behaviors that make disruption necessary.
The Brandi Glanville story is a useful lens here. A celebrity with resources, public platforms, and access to expert help still spent three years without a diagnosis, nearly $200,000 in bills, and faced opaque drug pricing even after she had answers. If the system can fail someone like Glanville, it's not hard to imagine what it does to patients without her platform.
The Break Up Big Medicine Act may not pass in this Congress. But the conversation Cuban is forcing — publicly, bluntly, at high-profile forums — has a way of shifting what's politically possible over time. The senators who privately support the bill but won't say so are already a step closer than they were a year ago. Whether Cuban's pressure, combined with bipartisan frustration, can close that gap remains to be seen.
What's clear is that the problem he's describing isn't going away. Vertically integrated healthcare conglomerates will continue to grow unless structural action is taken. PBMs will continue to operate as black boxes unless transparency is mandated. And patients like Glanville will continue to navigate a system that seems designed to confuse them — unless someone, or something, forces it to change.
